Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07773454
PHASE1
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
Sponsor: Exelixis
View on ClinicalTrials.gov
Summary
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
Official title: A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors
Key Details
Gender
All
Age Range
12 Months - 17 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2026-09-30
Completion Date
2028-07-31
Last Updated
2026-08-19
Healthy Volunteers
No
Conditions
Interventions
DRUG
Zanzalintinib
Administered as specified in the treatment arm.